Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CNTX Context Therapeutics

Watchlist
2.120
-0.080-3.64%
Close 06/30 16:00 ET
2.12000.00%
Post Mkt Price 06/30 16:09 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.189
Open
2.150
Turnover
784.43K
Low
2.050
Pre Close
2.200
Volume
372.35K
Market Cap
33.85M
P/E(TTM)
Loss
52wk High
10.870
Shares
15.97M
P/E(Static)
Loss
52wk Low
1.270
Float Cap
19.45M
Bid/Ask %
-33.33%
Historical High
10.870
Shs Float
9.17M
Volume Ratio
0.78
Historical Low
1.270
Dividend TTM
--
Div Yield TTM
--
P/B
0.75
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.06%
Amplitude
6.32%
Avg Price
2.106
Lot Size
1
Float Cap
19.45M
Bid/Ask %
-33.33%
Historical High
10.870
Shs Float
9.17M
Volume Ratio
0.78
Historical Low
1.270
Dividend TTM
--
P/B
0.75
Dividend LFY
--
Turnover Ratio
4.06%
Amplitude
6.32%
Avg Price
2.106
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CEO: Lehr, Martin A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top